Gil Roth11.05.13
Preclinical
Omeros gets good results for AMD mAb . . . read more
Phase I
ImmunoGen starts ADC trial . . . read more
OncoMed hits dose escalation milestone . . . read more
Phase II
Alcobra completes ADHD enrollment . . . read more
Genkyotex starts NOX inhibitor trial . . . read more
Keryx hits targets in NDD-CKD trial . . . read more
Serodus enrolls patients for ISH trial . . . read more
Phase III
CEL-SCI receives positive safety news for Multikine trial . . . read more
Reviva cleared to advance candidate against schizophrenia . . . read more
Shire's Vynase performs well against binge eating . . . read more
Filings
Aeterna Zentaris files NDA for AGHD . . . read more
Immunomedics gais TROP-2 antibody patent . . . read more
Repros discusses endpoints with FDA . . . read more
Omeros gets good results for AMD mAb . . . read more
Phase I
ImmunoGen starts ADC trial . . . read more
OncoMed hits dose escalation milestone . . . read more
Phase II
Alcobra completes ADHD enrollment . . . read more
Genkyotex starts NOX inhibitor trial . . . read more
Keryx hits targets in NDD-CKD trial . . . read more
Serodus enrolls patients for ISH trial . . . read more
Phase III
CEL-SCI receives positive safety news for Multikine trial . . . read more
Reviva cleared to advance candidate against schizophrenia . . . read more
Shire's Vynase performs well against binge eating . . . read more
Filings
Aeterna Zentaris files NDA for AGHD . . . read more
Immunomedics gais TROP-2 antibody patent . . . read more
Repros discusses endpoints with FDA . . . read more